# A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors

> **NCT06643754** · PHASE1,PHASE2 · RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 115 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** SHR-3276

## Key facts

- **NCT ID:** NCT06643754
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-10
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 115 (ESTIMATED)
- **Last updated:** 2025-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06643754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06643754, "A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06643754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*